Stephen Kanes, Chief Medical Officer at Sage Therapeutics, Inc. (SAGE), sold 4,936 shares at $69.60 ($347K) on 2015-07-27, disclosed to the SEC on 2015-07-29.
Scheduled sale ($347k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.50 | 636 | $44K | 12.6% |
| 2 | $68.67 | 654 | $45K | 13.0% |
| 3 | $69.38 | 800 | $56K | 16.0% |
| 4 | $69.60 | 900 | $63K | 18.1% |
| 5 | $70.91 | 400 | $28K | 8.2% |
| 6 | $72.00 | 500 |
| $36K |
| 10.4% |
| 7 | $72.08 | 826 | $60K | 17.2% |
| 8 | $73.64 | 220 | $16K | 4.7% |
| Total | $70.24 avg | 4,936 | $347K | 100% |
| Filing → |
| SAGE | SELL | 2016-04-21 | $798K | — | Filing → |
| SAGE | SELL | 2015-09-29 | $279K | — | Filing → |
| SAGE | SELL | 2015-09-01 | $637K | — | Filing → |